A regularly updated website with all most recent clinical trials data in HCV infection
BACK TO HOMEPAGE
NASH : A Summary
CENICRIVIROC
CENTAUR Study: cenicriviroc in NASH (phase 2b)
Friedman SL, Hepatology 2018;67:1754-67, Ratziu , EASL 2018, Abs. GS-002
SELONSERTIB
Selonsertib in NASH: phase 2
Loomba R, Hepatology 2018;67:549-59
Selonsertib + GS-0976 or GS-9674 in NASH
Lawitz E, EASL 2018, Abs. PS-105
GS-9674
GS-9674 in NASH: a phase 2 study
Patel K, AASLD 2018, Abs. 736
NGM282
NGM282 in NASH: 3 mg vs 6 mg QD (phase 2)
Harrison SA, Lancet 2018;391:1174-85
NGM282 in NASH: 3 mg QD (phase 2)
Harrison SA, EASL 2018, Abs. GS-014
NGM282, NAS and fibrosis in NASH: a phase 2 study
Harrison SA, AASLD 2018, Abs. 104
Aramchol
ARREST Study: Phase 2b of Aramchol in NASH
Ratziu V, AASLD 2018, Abs. LB5
Tropifexor
FLIGHT-FXR Study: Tropifexor (LJN452) in NASH: phase 2b (interim results)
Sanyal AJ, AASLD 2018, Abs. LB-23
VK2809
VK2809 in NAFLD: a phase 2 study
Loomba R, AASLD 2018, Abs. LB4
